CA1103314A - Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline - Google Patents
Cellule beta artificielle pour controler la perfusion d'une quantite d'insulineInfo
- Publication number
- CA1103314A CA1103314A CA297,510A CA297510A CA1103314A CA 1103314 A CA1103314 A CA 1103314A CA 297510 A CA297510 A CA 297510A CA 1103314 A CA1103314 A CA 1103314A
- Authority
- CA
- Canada
- Prior art keywords
- insulin
- blood glucose
- rate
- infusion
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 182
- 102000004877 Insulin Human genes 0.000 title claims abstract description 91
- 108090001061 Insulin Proteins 0.000 title claims abstract description 91
- 229940125396 insulin Drugs 0.000 title claims abstract description 91
- 238000001802 infusion Methods 0.000 title claims abstract description 33
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 title claims abstract description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 72
- 239000008103 glucose Substances 0.000 claims abstract description 72
- 239000008280 blood Substances 0.000 claims abstract description 48
- 210000004369 blood Anatomy 0.000 claims abstract description 48
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 4
- 230000015556 catabolic process Effects 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 238000009792 diffusion process Methods 0.000 claims description 6
- 238000004364 calculation method Methods 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 2
- 208000002230 Diabetic coma Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229940122254 Intermediate acting insulin Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA297,510A CA1103314A (fr) | 1978-02-21 | 1978-02-21 | Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA297,510A CA1103314A (fr) | 1978-02-21 | 1978-02-21 | Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1103314A true CA1103314A (fr) | 1981-06-16 |
Family
ID=4110840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA297,510A Expired CA1103314A (fr) | 1978-02-21 | 1978-02-21 | Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1103314A (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536249A (en) * | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
| US5820602A (en) * | 1995-09-08 | 1998-10-13 | Visionary Medical Products, Inc. | Pen-type injector drive mechanism |
| US6613011B2 (en) | 2001-04-13 | 2003-09-02 | Penjet Corporation | Gas-pressured engine with valve |
| US7018356B2 (en) | 2002-10-31 | 2006-03-28 | Wise Roger R | Method and apparatus for adjusting the contents of a needle-less injector |
-
1978
- 1978-02-21 CA CA297,510A patent/CA1103314A/fr not_active Expired
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5536249A (en) * | 1994-03-09 | 1996-07-16 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
| US5593390A (en) * | 1994-03-09 | 1997-01-14 | Visionary Medical Products, Inc. | Medication delivery device with a microprocessor and characteristic monitor |
| US5728074A (en) * | 1994-03-09 | 1998-03-17 | Visionary Medical Products, Inc. | Pen-type injector with a microprocessor and blood characteristic monitor |
| US5925021A (en) * | 1994-03-09 | 1999-07-20 | Visionary Medical Products, Inc. | Medication delivery device with a microprocessor and characteristic monitor |
| US5820602A (en) * | 1995-09-08 | 1998-10-13 | Visionary Medical Products, Inc. | Pen-type injector drive mechanism |
| US6613011B2 (en) | 2001-04-13 | 2003-09-02 | Penjet Corporation | Gas-pressured engine with valve |
| US7018356B2 (en) | 2002-10-31 | 2006-03-28 | Wise Roger R | Method and apparatus for adjusting the contents of a needle-less injector |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shichiri et al. | Normalization of the paradoxic secretion of glucagon in diabetics who were controlled by the artificial beta cell | |
| Mirouze et al. | Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes | |
| CA1040271A (fr) | Cellule beta artificielle | |
| Kawamori et al. | Importance of insulin secretion based on the rate of change in blood glucose concentration in glucose tolerance, assessed by the artificial beta cell | |
| Dimitriadis et al. | Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus | |
| Sigal et al. | Hyperinsulinemia prevents prolonged hyperglycemia after intense exercise in insulin-dependent diabetic subjects | |
| US4245634A (en) | Artificial beta cell | |
| Raskin et al. | Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps | |
| GB1574267A (en) | Apparatus for controlling a quantity of insulin infusion | |
| SACKS et al. | Similar responsiveness of diabetic ketoacidosis to low-dose insulin by intramuscular injection and albumin-free infusion | |
| Tsujimoto et al. | Rapid onset of glycogen storage hepatomegaly in a type-2 diabetic patient after a massive dose of long-acting insulin and large doses of glucose | |
| Kawamori et al. | Mechanism of exercise-induced hypoglycemia in depancreatized dogs maintained on long-acting insulin. | |
| Madsbad et al. | The transient effect of strict glycaemic control on B cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients | |
| Lauritzen et al. | Importance of insulin absorption, subcutaneous blood flow, and residual beta‐cell function in insulin therapy | |
| Martin et al. | Continuous low-dose infusion of insulin in the treatment of diabetic ketoacidosis in children | |
| Ferrannini et al. | Pattern of insulin delivery after intravenous glucose injection in man and its relation to plasma glucose disappearance. | |
| Kanarek et al. | Continuous infusion of insulin in hyperglycemic low‐birth weight infants receiving parenteral nutrition with and without lipid emulsion | |
| Gauthier et al. | Importance of glucagon in regulatory rather than emergency responses to hypoglycemia | |
| CA1103314A (fr) | Cellule beta artificielle pour controler la perfusion d'une quantite d'insuline | |
| Gormley et al. | One month's insulin treatment of type II diabetes: the early and medium-term effects following insulin withdrawal | |
| Skor et al. | Relative roles of insulin clearance and insulin sensitivity in the prebreakfast increase in insulin requirements in insulin-dependent diabetic patients | |
| Stevenson et al. | Matched glucose responses to insulin administered subcutaneously and intravenously: Evidence for subcutaneous inactivation of insulin | |
| Sherwin et al. | Treatment of juvenile-onset diabetes by subcutaneous infusion of insulin with a portable pump | |
| Jeng et al. | How does glibenclamide lower plasma glucose concentration in patients with type 2 diabetes? | |
| Goldstein et al. | Effects of an acute increase in epinephrine and cortisol on carbohydrate metabolism during insulin deficiency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |